Back to Stocks

CALC

CalciMedica, Inc.
2 filings tracked
healthcarebiotechnologyMICRO (<$300M)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

CalciMedica is executing a strategic capital reset, prioritizing operational efficiency and focused development as it approaches critical regulatory milestones.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

The narrative of capital efficiency masks a precarious financial position characterized by an unsustainable cash burn and a lack of near-term clinical catalysts.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every CALC filing.

Start Free Trial

Synthesis (Verdict & Resolution)

CalciMedica's Q1 2026 filing presents a company at a crossroads, balancing aggressive cost-cutting against severe liquidity constraints and clinical setbacks. While management has successfully streamlined the balance sheet and reduced operational overhead, the fundamental risk remains the binary nature of its regulatory path. The pause of the KOURAGE trial creates a void in the immediate catalyst pipeline, shifting all investor focus to the upcoming FDA feedback regarding the acute pancreatitis program. The overall impact of the filing is a heightened risk profile. The transition to a 'lean' model is a necessary survival tactic given the $184.4 million accumulated deficit and the 'going concern' warning issued by management. For investors, the trade-off is clear: the potential for a first-in-class therapeutic breakthrough against the very real possibility of a cash crunch that could trigger a dilutive equity offering or a total loss of capital before the 2027 IND targets are met.

Selected Quarter

Core Takeaway

CalciMedica has slashed costs and reduced liabilities to extend its runway, but a paused lead trial and minimal cash reserves leave the company in a high-risk, high-reward state.

Investor Lens

The trade-off is between the potential of a first-in-class CRAC inhibitor and the immediate risk of a liquidity event.

Watch Next

FDA feedback on the acute pancreatitis program design expected in Q2 2026.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)-0.23Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 12

Operating expenses decreased by 14% year-over-year through disciplined cost cutting.

margin expansion
60%
neutralMay 12

Filed a new $125 million shelf registration to provide future funding options.

capital raise
50%
bearishMay 12

Pause in KOURAGE Phase 2 trial due to safety concerns (mortality imbalance).

regulatory action
80%
bearishMay 12

High-interest loan (12.75% floor) with restrictive covenants limits financial flexibility.

debt restructure
70%
bullishMay 12

Operating expenses decreased by 14% year-over-year through disciplined cost cutting.

margin expansion
60%
neutralMay 12

Filed a new $125 million shelf registration to provide future funding options.

capital raise
50%
bearishMay 12

Pause in KOURAGE Phase 2 trial due to safety concerns (mortality imbalance).

regulatory action
80%
bearishMay 12

High-interest loan (12.75% floor) with restrictive covenants limits financial flexibility.

debt restructure
70%

Filing History

10-QMay 12, 2026
Expand Sequence

CalciMedica's Q1 2026 filing presents a company at a crossroads, balancing aggressive cost-cutting against severe liquidity constraints and clinical setbacks. While management has successfully streamlined the balance sheet and reduced operational overhead, the fundamental risk remains the binary nature of its regulatory path. The pause of the KOURAGE trial creates a void in the immediate catalyst pipeline, shifting all investor focus to the upcoming FDA feedback regarding the acute pancreatitis program. The overall impact of the filing is a heightened risk profile. The transition to a 'lean' model is a necessary survival tactic given the $184.4 million accumulated deficit and the 'going concern' warning issued by management. For investors, the trade-off is clear: the potential for a first-in-class therapeutic breakthrough against the very real possibility of a cash crunch that could trigger a dilutive equity offering or a total loss of capital before the 2027 IND targets are met.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.